DALLAS, February 20, 2015 /PRNewswire/ —
Global and Chinese Human Insulin Industry, 2009-2019 Market Research Report and Human Insulin Market by Product Type (Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed), by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) – Forecast to 2018 are research reports now available with LifeScienceIndustryResearch.com.
Countries such as China, India, Japan, and Korea will offer potential growth opportunities to human insulin market. Of all the countries, China is estimated to be the fastest growing market for human insulin market. Saudi Arabia, Qatar, Egypt, U.A.E, and Brazil will also emerge as lucrative markets for human insulin market. The ‘ Global and Chinese Human Insulin Industry, 2009-2019 Market Research Report’ is a professional and in-depth study on the current state of the global Human Insulin industry with a focus on the Chinese market. The report provides key statistics on the market status of the Human Insulin manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Complete report is available at http://www.lifescienceindustryresearch.com/global-and-chinese-human-insulin-industry-2009-2019-market-research-report.html .
Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2009-2014 market shares for each company. Through the statistical analysis, the report depicts the global and Chinese total market of Human Insulin industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 2014-2019 market development trends of Human Insulin industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Human Insulin Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2009-2019 global and Chinese Human Insulin industry covering all important parameters. Order a copy of this research at http://www.lifescienceindustryresearch.com/purchase?rname=27425 .
Modern human insulin accounted for the largest share -84%- of global human insulin market. Premixed modern human insulin and long acting human insulin are estimated to grow at a brisk pace over the next five years. The high growth in these segments can be attributed to the growing demand of Apidra, Lantus, and Levemir. Furthermore, these drugs reported high efficiency and effectiveness as compared to other synthetic insulin, animal insulin, and other human insulin. The research on Human Insulin Market by Product Type (Human Insulin (Short Acting, Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, Long Acting, Premixed), by Brand (Lantus, Apidra, Levemir, NovoRapid, Novomix, Tresiba, Others) – Forecast to 2018 is spread across 250 pages.
New technologies such as safety pen needles and infusion pumps have emerged as efficient mode of delivery for human insulin. Pen needles offer significant benefits to the healthcare sector. The usage of easy to fit needles is rising due to the convenience offered by them. These needles are easy to attach, remove, and dispose, thus they can be easily used by patients with manual dexterity problems, and visual impairment. Diabetes educators and clinicians across the world recommend the usage of needles with shorter lengths and higher gauge sizes for convenience and to minimize pain. Owing to these factors, technological advancement is expected to be a major revenue pocket for the human insulin market in the coming years.
Above all, most of the early biologic human insulin lost their patent protection in the first half of the 20th century, while many of the current best-selling drugs such as insulin glargine, insulin as part, and insulin lispro are all set to lose their patent protection in the coming years. This creates new opportunities for biosimilar drugs which is estimated to grow at a CAGR of 35% from 2014-2019.
The grey area while estimating the market size is the variable price of human insulin across the globe as it differs widely across each country.
From an insight perspective, this research report focuses on the qualitative data, market size, share, and growth of various segments and sub-segments, competitive landscape, and company profiles for Novo Nordisk, EliLilly, Sanofi Aventis, Biocon and Julphar Pharmaceuticals. Human insulin brands like Actrapid, Mixtard, Insulatard, Humulin, Insum, An, Lantus, Novorapid/Novolog, Humalog, Levemir, Novomix, Apidra and Tresiba are also discussed in this research available for purchase at http://www.lifescienceindustryresearch.com/purchase?rname=15837 .
Explore more reports on the pharmaceuticals market at http://www.lifescienceindustryresearch.com/category/pharmaceuticals .
Life Science Industry Research brings to you to the latest reports in market research on Biotechnology, Diagnostics, Healthcare, Medical Devices and Pharmaceuticals segments from leading research publishers across the globe. These reports also cover data and information on sub-segments and sectors under these life sciences categories.
Contact: Ritesh Tiwari / Siju K.TX, Dallas North – Dominion Plaza,17304, Preston Road,Suite 800, Dallas 75252Tel: +1-888-391-5441E-mail: firstname.lastname@example.org
SOURCE Life Science Industry Research
DALLAS, February 20, 2015 /PRNewswire/ —